GlucoTrack, Inc. develops medical technology for people with diabetes, centered on a long-term, fully implantable continuous blood glucose monitoring system. Company news commonly covers the CBGM platform, FDA Investigational Device Exemption activity, preclinical and clinical-study disclosures, and peer-reviewed publications on sensor stability, accuracy, and implantable device performance.
Updates also include intellectual-property developments for proprietary sensor chemistry, intravascular lead design, and low-power electronics, along with financial results, research and development spending, capital actions, and conference presentations tied to the company’s diabetes device strategy.
GlucoTrack, Inc. (Nasdaq: GCTK) announced the launch of a new R&D program aimed at developing a long-term implantable glucose monitor targeting the Type 1 diabetes market. Following the acquisition of related intellectual property, the company aims to create a more accurate and convenient glucose management solution. GlucoTrack also reported positive lab testing results for its non-invasive GlucoTrack 2.0 prototype, with first-in-human trials expected to begin soon. CEO Paul Goode expressed excitement about expanding their product pipeline to benefit people with diabetes.
GlucoTrack, Inc. (Nasdaq: GCTK) provided an update on its GlucoTrack 2.0 development, revealing successful lab testing of its clinical prototype. The company achieved better-than-expected accuracy and performance in bench tests and obtained Ethics Committee approvals for its first in-human clinical study at Rabin Medical Center, Israel, slated for Q3. The forthcoming U.S. study will follow, leading towards FDA clearance. The new design aims for improved user-friendliness and lower costs. CEO Paul Goode expressed optimism about the progress made.
GlucoTrack, Inc. (Nasdaq: GCTK), previously known as Integrity Applications, Inc. (Nasdaq: IGAP), has officially changed its corporate name and ticker symbol as of March 14, 2022. This transition reflects the company's focus on non-invasive glucose monitoring technologies for Type 2 diabetes and prediabetes. The name and symbol changes do not affect stockholder rights or outstanding shares. Shareholders holding physical certificates will receive instructions for exchanging them. GlucoTrack’s device aims to provide a pain-free alternative to traditional glucose monitoring methods.